Clinical Trial Update: GSK618334 Repeat Dose Study [Phase 1]

View source ↗

Summary

GlaxoSmithKline's Phase 1 repeat-dose study of the investigational compound GSK618334 for substance dependence has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Dependence

Drugs mentioned

• GSK618334

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED